Immutep (IMMP) announces it has received a EUR 2,588,954 research and development tax incentive payment in cash from the French Government under its Credit d’Impot Recherche scheme, CIR. The “Credit d’Impot Recherche,” meaning “Research Tax Credit,” is a French government tax incentive by which French companies conducting research and development activities in Europe can be reimbursed 30% of their eligible expenditure.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMP:
- Immutep Advances Key Clinical Trials and Strengthens Financial Position
- Immutep reports Q1 cash receipts from customers A$15,000
- Immutep Showcases Promising Lung Cancer Treatment Results at ESMO Congress 2025
- Immutep Announces Breakthrough Results in Soft Tissue Sarcoma Trial
- Immutep presents two posters at ESMO on changing landscape for 1L NSCLC